Published in Antimicrob Agents Chemother on January 09, 2012
Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2014) 1.24
Fosfomycin. Clin Microbiol Rev (2016) 0.89
Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2012) 0.88
Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS One (2013) 0.87
Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations. Antimicrob Agents Chemother (2015) 0.84
Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions. Antimicrob Agents Chemother (2013) 0.84
Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. Antimicrob Agents Chemother (2014) 0.82
Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination. Pathog Dis (2013) 0.80
Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: Experimental Basis for Combination Therapy. Antimicrob Agents Chemother (2016) 0.75
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2003) 10.63
The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci (1974) 7.21
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med (1999) 6.23
Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of Salmonella typhimurium cya and crp mutants. J Bacteriol (1978) 4.91
Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev (2006) 4.39
Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev (2003) 3.72
Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev (1987) 3.31
Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother (2000) 3.27
Kinetics of transport of glucose, fructose, and mannitol by Pseudomonas aeruginosa. Can J Biochem (1971) 2.54
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol (2009) 2.53
Transport and phosphorylation of glucose, fructose, and mannitol by Pseudomonas aeruginosa. Arch Biochem Biophys (1970) 2.48
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol (2010) 2.11
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J (2002) 2.02
Amino acid transport in Pseudomonas aeruginosa. J Bacteriol (1969) 2.00
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother (2003) 1.89
Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol (2005) 1.85
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis (1985) 1.85
Some observations on the penetration of antibiotics through mucus in vitro. J Clin Pathol (1966) 1.84
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest (2002) 1.65
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
The CbrA-CbrB two-component regulatory system controls the utilization of multiple carbon and nitrogen sources in Pseudomonas aeruginosa. Mol Microbiol (2001) 1.59
Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol (1976) 1.48
The gate controlling cell wall synthesis in Staphylococcus aureus. Mol Microbiol (2004) 1.47
MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med (2007) 1.30
Transport of glycerol by Pseudomonas aeruginosa. J Bacteriol (1971) 1.28
MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 1.27
Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother (2006) 1.27
Aminoglycoside-resistant mutants of Pseudomonas aeruginosa deficient in cytochrome d, nitrite reductase, and aerobic transport. Antimicrob Agents Chemother (1981) 1.27
The OprB porin plays a central role in carbohydrate uptake in Pseudomonas aeruginosa. J Bacteriol (1995) 1.23
Role of the novel OprD family of porins in nutrient uptake in Pseudomonas aeruginosa. J Bacteriol (2006) 1.22
Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother (2008) 1.20
Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother (1995) 1.19
Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol Microbiol (2006) 1.19
Regulation of carbon and nitrogen utilization by CbrAB and NtrBC two-component systems in Pseudomonas aeruginosa. J Bacteriol (2007) 1.12
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother (2009) 1.12
Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother (2007) 1.11
Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. PLoS One (2010) 1.11
The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol (2009) 1.09
High-throughput phenotypic characterization of Pseudomonas aeruginosa membrane transport genes. PLoS Genet (2008) 1.09
Pharmacokinetics of antibiotics in the lungs. Eur Respir J (1990) 1.09
Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother (2002) 1.06
The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother (1988) 1.06
Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K--12. J Antibiot (Tokyo) (1978) 1.04
Regulation of glycerol metabolism in Pseudomonas aeruginosa: characterization of the glpR repressor gene. J Bacteriol (1996) 1.01
Use of streptomycin and cyclic adenosine 5'-monophosphate in the isolation of mutants deficient in CAP protein. J Bacteriol (1974) 0.99
Adaptations of Pseudomonas aeruginosa to the cystic fibrosis lung environment can include deregulation of zwf, encoding glucose-6-phosphate dehydrogenase. J Bacteriol (2005) 0.97
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros (2003) 0.95
Involvement of two related porins, OprD and OpdP, in the uptake of arginine by Pseudomonas aeruginosa. FEMS Microbiol Lett (2006) 0.94
The effect of nutrient limitation on glycerol uptake and metabolism in continuous cultures of Pseudomonas aeruginosa. Microbiology (1994) 0.94
Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase. Eur J Biochem (2004) 0.93
Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme. Antimicrob Agents Chemother (2001) 0.90
Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes. J Am Chem Soc (2009) 0.88
MUC5B secretion is up-regulated in sinusitis compared with controls. Am J Rhinol (2006) 0.87
An enzyme-linked immunosorbent assay (ELISA) for the determination of mucin levels in bronchoalveolar lavage fluid. J Pharmacol Toxicol Methods (2005) 0.85
Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1987) 0.84
Experimental endocarditis and fosfomycin. Drugs Exp Clin Res (1985) 0.84
A new synthesis of the antibiotic phosphonomycin. J Org Chem (1970) 0.77
Structures and biological activities of tobramycin-ticarcillin adducts. J Pharm Sci (1994) 0.77
A new mucotropic agent--in vitro and in vivo evaluation of 2-alpha-thenoylthiopropionylglycine (bronchoplus). Eur J Respir Dis (1985) 0.77
Essential role of ferritin Pfr in Helicobacter pylori iron metabolism and gastric colonization. Infect Immun (2002) 1.43
Alternative sigma factor interactions in Salmonella: sigma and sigma promote antioxidant defences by enhancing sigma levels. Mol Microbiol (2005) 1.29
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother (2009) 1.12
Acid stress activation of the sigma(E) stress response in Salmonella enterica serovar Typhimurium. Mol Microbiol (2009) 0.93
A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids. J Med Chem (2004) 0.87
Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. Am J Physiol Lung Cell Mol Physiol (2013) 0.85
Noninvasive measurement of pH in platelet concentrates with a fiber optic fluorescence detector. Transfusion (2009) 0.84
The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist. J Pharmacol Exp Ther (2014) 0.82
Extraction of MS2 phage RNA from upper respiratory tract specimens by use of flat glass devices. J Clin Microbiol (2010) 0.81
Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination. Pathog Dis (2013) 0.80